Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Dose Finding Study of Different MOD-4023 Dose Levels Compared to Daily r-hGH Therapy in Pre-pubertal Growth Hormone Deficient Children

Next Previous
X
Search
Trial Profile

Safety and Dose Finding Study of Different MOD-4023 Dose Levels Compared to Daily r-hGH Therapy in Pre-pubertal Growth Hormone Deficient Children

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Somatrogon (Primary) ; Somatropin
  • Indications Somatotropin deficiency
  • Focus Therapeutic Use
  • Sponsors OPKO Health; PROLOR Biotech

    • Most Recent Events

    • 18 Jun 2023 Results assessing long term efficacy and safety of somatrogon in pGHD presented at the 105th Annual Meeting of the Endocrine Society
    • 20 Mar 2023 Results following 5 years of treatment, published in the Journal of Pediatric Endocrinology and Metabolism
    • 31 Jan 2017 Results published in the Journal of Clinical Endocrinology and Metabolism

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top